300485 赛升药业
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.1380.433-2.0273.0236.187
总资产报酬率 ROA (%)0.1310.409-1.9202.8625.874
投入资产回报率 ROIC (%)0.1340.421-1.9702.9366.064

边际利润分析
销售毛利率 (%)68.10665.11566.28270.42676.638
营业利润率 (%)4.0903.068-19.92325.54434.666
息税前利润/营业总收入 (%)4.9442.829-20.47025.41434.602
净利润/营业总收入 (%)4.2191.925-18.45820.23027.588

收益指标分析
经营活动净收益/利润总额(%)196.871-96.322-30.401-33.6269.430
价值变动净收益/利润总额(%)-137.270301.910129.395131.03383.309
营业外收支净额/利润总额(%)16.731-0.9140.7090.349-0.008

偿债能力分析
流动比率 (X)20.08918.28420.86026.30017.621
速动比率 (X)19.26817.53819.86824.21916.432
资产负债率 (%)4.7644.9314.6874.2684.402
带息债务/全部投入资本 (%)0.7530.6870.1080.1720.253
股东权益/带息债务 (%)12,856.40314,110.89190,494.81556,495.61338,469.304
股东权益/负债合计 (%)1,986.8921,915.8322,016.5132,222.3702,147.677
利息保障倍数 (X)154.837-13.43350.480-115.483-563.178

营运能力分析
应收账款周转天数 (天)40.46539.90340.74446.43140.964
存货周转天数 (天)219.059191.516241.526250.518222.522